[Assessment of criteria for forming follow-up groups of patients at high risk for ulcerogenesis in ambulatory care]. / Otsenka kriteriev formirovaniia grupp nabliudeniia sredi lits s faktorami vysokogo riska ul'tserogeneza v usloviiakh polikliniki.

A method of clinico-laboratory examinations to reveal persons at high risk for the development of duodenal ulcer, suitable for wide use during prophylactic medical screenings was devised. The rise of the levels of serum pepsinogen-I, pepsin and hexosamines in the urine, being of prognostic importance as applicable to ulcerogenesis, was the most significant indicator in screening risk group patients. During 3 to 5 years of the screened group follow-up and carrying out health measures, peptic ulcer was ascertained in 8.4% of the patients with chronic gastroduodenitis. Of these, 66.6% had initially suffered from pylorobulbitis. It is shown that there is a real opportunity of preventing ulcer formation in patients with chronic primary gastroduodenitis under outpatient conditions.

[Preventive chemotherapy of duodenal ulcer]. / Profilakticheskaia farmakoterapiia iazvennoi bolezni dvenadtsati- perstnoi kishki.

An attempt was made to solve the problem in preventive drug therapy for duodenal ulcer in terms of various types of the course of the disease, its heterogeneity, features of metabolic processes, a patient's age, individual selection of the optimal drug, its dosage, regimen, intake duration, which would provide a differential individual design of drug therapy and change multicomponent drug therapy by mono- or diet therapy. Pharmacokinetic features of currently available antiulcer agents of groups of pyrenezepine or H2-blockers of histamine are presented, which should be taken into account when these drugs are used. A relationship is shown between the pharmacokinetics of drugs to an immune response as production of specific anti-drug++ antibodies that occasionally cause inefficiency of the therapy performed and a relapse of the disease during continuous treatment. The outcomes of differential preventive therapy are given in various types of the course of duodenal ulcer.

[Cellular and humoral immunity in duodenal peptic ulcer with gastrin cell hyperplasia]. / Kletochnyi i gumoral'nyi immunitet pri iazvennoi bolezni dvenadtsatiperstnoi kishki s giperplaziei gastrinovykh kletok.

A total of 61 patients with frequently relapsing duodenal ulcer were examined. Of these, 18 patients were in the acute phase and 43 experienced remission. Using 1 mm2 of the mucosa, measurements were made of the counts of duodenal and pyloric G-cells (by immunomorphologic assay), of the absolute and relative counts of T and B lymphocytes, the content of IgA, IgM and IgG, histamine and serotonin (by fluorometry) in the blood, and of the concentration of uropepsin in the urine. In the stages of exacerbation and remission, the patients suffering from duodenal ulcer with hyperplasia of G-cells manifested, as compared with the analogous patients without hyperplasia, a decrease of the absolute and relative counts of T cells, especially of those of B cells, combined with a rise of the content of IgM and IgG during exacerbation, followed by its returning to normal in the phase of remission. Over one year part of the duodenal ulcer patients with hyperplasia of G-cells received preventive treatment with ranitidine, which resulted in a tendency towards the lowering of the count of pyloric G-cells and the rise of the absolute and relative counts of T cells.